These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32778510)

  • 1. A Case of Resistance to Selective RET-TKI Therapy With Pleural-Genotyped MET Amplification and Response to Crizotinib.
    Chen K; Zhang F; Pan G; Sheng J; Ye J; Xu Y; Yu X; Huang Z; Fan Y
    Clin Lung Cancer; 2021 Jan; 22(1):e1-e4. PubMed ID: 32778510
    [No Abstract]   [Full Text] [Related]  

  • 2. Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
    Rosen EY; Johnson ML; Clifford SE; Somwar R; Kherani JF; Son J; Bertram AA; Davare MA; Gladstone E; Ivanova EV; Henry DN; Kelley EM; Lin M; Milan MSD; Nair BC; Olek EA; Scanlon JE; Vojnic M; Ebata K; Hechtman JF; Li BT; Sholl LM; Taylor BS; Ladanyi M; Jänne PA; Rothenberg SM; Drilon A; Oxnard GR
    Clin Cancer Res; 2021 Jan; 27(1):34-42. PubMed ID: 33082208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Responses to crizotinib can occur in c-MET overexpressing nonsmall cell lung cancer after developing EGFR-TKI resistance.
    Xu Y; Fan Y
    Cancer Biol Ther; 2019; 20(2):145-149. PubMed ID: 30422759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.
    van Veggel B; de Langen AJ; Hashemi S; Monkhorst K; Rosenberg EH; Heideman DAM; Radonic T; Smit EF
    Lung Cancer; 2018 Oct; 124():130-134. PubMed ID: 30268451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
    Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
    J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crizotinib plus erlotinib overcomes osimertinib resistance in a seriously-ill non-small cell lung cancer patient with acquired MET amplification.
    Zhao ZM; Wang SP; Sun L; Ji YX
    Chin Med J (Engl); 2020 Nov; 134(3):373-374. PubMed ID: 33186133
    [No Abstract]   [Full Text] [Related]  

  • 7. Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.
    Jin W; Shan B; Liu H; Zhou S; Li W; Pan J; Lin L; Hu D; Pan Y
    J Thorac Oncol; 2019 Jul; 14(7):e137-e139. PubMed ID: 31055074
    [No Abstract]   [Full Text] [Related]  

  • 8. Crizotinib in
    Landi L; Chiari R; Tiseo M; D'Incà F; Dazzi C; Chella A; Delmonte A; Bonanno L; Giannarelli D; Cortinovis DL; de Marinis F; Borra G; Morabito A; Gridelli C; Galetta D; Barbieri F; Grossi F; Capelletto E; Minuti G; Mazzoni F; Verusio C; Bria E; Alì G; Bruno R; Proietti A; Fontanini G; Crinò L; Cappuzzo F
    Clin Cancer Res; 2019 Dec; 25(24):7312-7319. PubMed ID: 31416808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
    Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
    Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PAI-1 mediates acquired resistance to MET-targeted therapy in non-small cell lung cancer.
    Thu YM; Suzawa K; Tomida S; Ochi K; Tsudaka S; Takatsu F; Date K; Matsuda N; Iwata K; Nakata K; Shien K; Yamamoto H; Okazaki M; Sugimoto S; Toyooka S
    PLoS One; 2024; 19(5):e0300644. PubMed ID: 38758826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib.
    Berger LA; Janning M; Velthaus JL; Ben-Batalla I; Schatz S; Falk M; Iglauer P; Simon R; Cao R; Forcato C; Manaresi N; Bramlett K; Buson G; Hanssen A; Tiemann M; Sauter G; Bokemeyer C; Riethdorf S; Reck M; Pantel K; Wikman H; Loges S
    J Thorac Oncol; 2018 Dec; 13(12):e243-e246. PubMed ID: 30205165
    [No Abstract]   [Full Text] [Related]  

  • 12. Effective assessment of low times MET amplification in pleural effusion after epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) acquired resistance: Cases report.
    Wang CG; Zeng DX; Huang JA; Jiang JH
    Medicine (Baltimore); 2018 Jan; 97(1):e9021. PubMed ID: 29505507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy.
    Wang Y; Tian P; Xia L; Li L; Han R; Zhu M; Lizaso A; Qin T; Li M; Yu B; Mao X; Han-Zhang H; He Y
    Lung Cancer; 2020 Aug; 146():165-173. PubMed ID: 32540560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liquid biopsy for the detection of resistance mutations to ROS1 and RET inhibitors in non-small lung cancers: A case series study.
    Seki Y; Yoshida T; Kohno T; Masuda K; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Kuwano K; Ohe Y
    Respir Investig; 2022 Nov; 60(6):852-856. PubMed ID: 36089506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
    Ou SI; Young L; Schrock AB; Johnson A; Klempner SJ; Zhu VW; Miller VA; Ali SM
    J Thorac Oncol; 2017 Jan; 12(1):137-140. PubMed ID: 27666659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An early look at selective RET inhibitor resistance: new challenges and opportunities.
    Lin JJ; Gainor JF
    Br J Cancer; 2021 May; 124(11):1757-1758. PubMed ID: 33758332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crizotinib in the management of advanced-stage non-small-cell lung cancer.
    Loong HH; Mok K; Leung LK; Mok TS
    Future Oncol; 2015; 11(5):735-45. PubMed ID: 25757678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. De Novo MET Amplification in Chinese Patients With Non-Small-Cell Lung Cancer and Treatment Efficacy With Crizotinib: A Multicenter Retrospective Study.
    Song Z; Wang H; Yu Z; Lu P; Xu C; Chen G; Zhang Y
    Clin Lung Cancer; 2019 Mar; 20(2):e171-e176. PubMed ID: 30554986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Modeling of ALK L1198F and/or G1202R Mutations to Determine Differential Crizotinib Sensitivity.
    Chuang YC; Huang BY; Chang HW; Yang CN
    Sci Rep; 2019 Aug; 9(1):11390. PubMed ID: 31388026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful Treatment of a Patient With NSCLC Harboring an EGFR Mutation and a Concomitant Met Exon 14 Skipping Mutation Combining Afatinib and Crizotinib.
    Kauffmann-Guerrero D; Kahnert K; Kumbrink J; Syunyaeva Z; Tufman A; Huber RM
    Clin Lung Cancer; 2019 Jan; 20(1):59-62. PubMed ID: 30341016
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.